![Citicoline injections 125 mg/ml 4 ml [5 ampoules]](https://mediscom.com.co/wp-content/uploads/2022/11/Citicoline-125mg-4ml-5.webp "Citicoline-125mg-4ml-5.webp")
Description
Citicoline injections 125 mg/ml Pharmacodynamics
Citicoline, being a precursor of the key ultrastructural components of the cell membrane (mainly phospholipids), has a broad spectrum of action: it helps restore damaged cell membranes, inhibits the action of phospholipases, prevents the excess formation of free radicals, and also prevents cell death by acting on apoptosis mechanisms. In the acute period of stroke citicoline reduces the volume of brain matter lesions, improves cholinergic transmission. In craniocerebral trauma reduces the duration of post-traumatic coma and severity of neurological symptoms, also contributes to reducing the duration of the recovery period
In chronic cerebral hypoxia citicoline is effective in treating cognitive disorders such as memory impairment, lack of initiative, difficulties in performing daily activities and self-care. It increases the level of attention and consciousness and reduces the manifestation of amnesia.
Citicoline injections 125 mg/ml are used in the treatment of sensory and motor neurological disorders of degenerative and vascular etiology.
Indications
– Acute phase of ischemic stroke (cerebral infarction) (as part of complex therapy).
– The recovery period of ischemic and hemorrhagic stroke.
– Craniocerebral trauma (CTS): acute (as part of the complex therapy) and recovery period
– Cognitive and behavioral disorders in degenerative and vascular diseases of the brain.
Contraindications
– Hypersensitivity to any of the drug components,
– Patients with severe vagotomy (predominance of the tone of the parasympathetic part of the autonomic nervous system),
– Children under 18 years of age (due to insufficient clinical data).
Administration during pregnancy and breastfeeding
There are insufficient data on the use of citicoline in pregnant women. Although no adverse effects were found in animal studies, during pregnancy the drug is prescribed only in cases when the expected benefits to the mother outweigh the potential risk to the fetus.
When prescribing the drug during lactation women should stop breastfeeding, because there is no data about citicoline excretion with breast milk, the risk to the baby can not be completely excluded.
Dosage and administration method
- The drug is administered intravenously or intramuscularly.
- Intravenously the drug is administered in the form of slow intravenous injection (within 3-5 minutes, depending on the prescribed dose) or intravenous drip infusion (40-60 drops per minute).
- The intravenous route of administration is preferable to the intramuscular route. When administering intramuscularly, avoid injecting the drug in the same place.
- Recommended dosing regimen.
- Acute period of ischemic stroke and traumatic brain injury (TBI): 1000 mg every 12 hours. Duration of treatment at least 6 weeks. In 3-5 days after the start of treatment (if swallowing function is not impaired) transition to oral forms of citicoline is possible
- The restorative period of ischemic and hemorrhagic strokes, the restorative period of CHT, cognitive and behavioral disorders in degenerative and vascular brain diseases: 500-2000 mg per day (1-2 times a day).
- Dosage and duration of treatment depending on the severity of the disease symptoms.
- Elderly patients.
- No dose adjustment is required when prescribing the drug in elderly patients.
- The solution in the ampoule is intended for single use. It should be used immediately after opening the ampoule.
- Citicoline injections 125 mg/ml are compatible with all types of intravenous isotonic solutions and dextrose solutions.
